INTRA-CELLULAR THERAPIES INC (ITCI) Stock Price, Quote, News and Overview
NASDAQ:ITCI - Nasdaq - US46116X1019 - Common Stock - Currency: USD
ITCI Quote, Performance and Key Statistics
128.54
-0.06 (-0.05%)
The current stock price of ITCI is 128.54 USD. In the past month the price increased by 1.09%. In the past year, price increased by 83.21%.
ITCI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.16 | 828.87B | ||
| JNJ | JOHNSON & JOHNSON | 15.98 | 384.45B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.17 | 371.73B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.65 | 231.22B | ||
| MRK | MERCK & CO. INC. | 11.48 | 221.80B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.52 | 211.95B | ||
| PFE | PFIZER INC | 8.33 | 146.78B | ||
| SNY | SANOFI-ADR | 13.53 | 135.71B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.94 | 113.15B | ||
| GSK | GSK PLC-SPON ADR | 7.88 | 75.42B | ||
| ZTS | ZOETIS INC | 26.59 | 71.02B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.5 | 43.94B |
Related stock screener links
About ITCI
Company Profile
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 610 full-time employees. The company went IPO on 2014-01-31. The firm leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
Company Info
INTRA-CELLULAR THERAPIES INC
135 Route 202/206, Suite 6
Bedminster NEW JERSEY 10016 US
CEO: Sharon Mates
Employees: 610
Company Website: https://www.intracellulartherapies.com/
Investor Relations: https://ir.intracellulartherapies.com/
Phone: 16464409333
INTRA-CELLULAR THERAPIES INC / ITCI FAQ
What is the stock price of INTRA-CELLULAR THERAPIES INC today?
The current stock price of ITCI is 128.54 USD. The price decreased by -0.05% in the last trading session.
What is the ticker symbol for INTRA-CELLULAR THERAPIES INC stock?
The exchange symbol of INTRA-CELLULAR THERAPIES INC is ITCI and it is listed on the Nasdaq exchange.
On which exchange is ITCI stock listed?
ITCI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INTRA-CELLULAR THERAPIES INC stock?
19 analysts have analysed ITCI and the average price target is 128.71 USD. This implies a price increase of 0.13% is expected in the next year compared to the current price of 128.54. Check the INTRA-CELLULAR THERAPIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INTRA-CELLULAR THERAPIES INC worth?
INTRA-CELLULAR THERAPIES INC (ITCI) has a market capitalization of 13.63B USD. This makes ITCI a Large Cap stock.
How many employees does INTRA-CELLULAR THERAPIES INC have?
INTRA-CELLULAR THERAPIES INC (ITCI) currently has 610 employees.
What are the support and resistance levels for INTRA-CELLULAR THERAPIES INC (ITCI) stock?
INTRA-CELLULAR THERAPIES INC (ITCI) has a support level at 127.78 and a resistance level at 128.55. Check the full technical report for a detailed analysis of ITCI support and resistance levels.
Is INTRA-CELLULAR THERAPIES INC (ITCI) expected to grow?
The Revenue of INTRA-CELLULAR THERAPIES INC (ITCI) is expected to grow by 44.2% in the next year. Check the estimates tab for more information on the ITCI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INTRA-CELLULAR THERAPIES INC (ITCI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ITCI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ITCI, evaluating the profitability, health, valuation and growth aspects
- INTRA-CELLULAR THERAPIES INC (ITCI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INTRA-CELLULAR THERAPIES INC (ITCI) Sales and EPS estimates to see what analysts future expectations are.
- INTRA-CELLULAR THERAPIES INC (ITCI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INTRA-CELLULAR THERAPIES INC (ITCI) Insider and Institutional Ownership to learn about the owners and their transactions.
- INTRA-CELLULAR THERAPIES INC (ITCI) Stock Chart to make your own analysis
- INTRA-CELLULAR THERAPIES INC (ITCI) Latest news and press-releases to stay up to date.
Does INTRA-CELLULAR THERAPIES INC (ITCI) stock pay dividends?
ITCI does not pay a dividend.
When does INTRA-CELLULAR THERAPIES INC (ITCI) report earnings?
INTRA-CELLULAR THERAPIES INC (ITCI) will report earnings on 2025-02-26, after the market close.
What is the Price/Earnings (PE) ratio of INTRA-CELLULAR THERAPIES INC (ITCI)?
INTRA-CELLULAR THERAPIES INC (ITCI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.87).
What is the Short Interest ratio of INTRA-CELLULAR THERAPIES INC (ITCI) stock?
The outstanding short interest for INTRA-CELLULAR THERAPIES INC (ITCI) is 1.57% of its float. Check the ownership tab for more information on the ITCI short interest.
ITCI Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ITCI. When comparing the yearly performance of all stocks, ITCI is one of the better performing stocks in the market, outperforming 95.49% of all stocks.
ITCI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ITCI. ITCI has a great financial health rating, but its profitability evaluates not so good.
ITCI Financial Highlights
Over the last trailing twelve months ITCI reported a non-GAAP Earnings per Share(EPS) of -0.87. The EPS increased by 45.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -6.52% | ||
| ROE | -7.54% | ||
| Debt/Equity | 0 |
ITCI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 72% to ITCI. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 50.56% and a revenue growth 44.2% for ITCI